
Wave Life Sciences: A biotech firm innovating disease-modifying drugs via proprietary synthetic chemistry.
Wave Life Sciences Ltd. was founded with the mission to revolutionize medicine through innovative synthetic chemistry and RNA-targeting modalities. The company focuses on designing, developing, and commercializing stereopure nucleic acid therapeutics aimed at treating both rare and prevalent disorders. By leveraging deep insights in human genetics, Wave Life Sciences aims to address high unmet medical needs, particularly in orphan diseases.
Notable affiliated individuals include leading scientists and industry experts who contribute to its pioneering research. The company has garnered significant investment from prominent biotech investors, fueling its ambitious projects. Key achievements include advancements in RNA-targeting therapies and successful pre-clinical trials, positioning Wave Life Sciences as a transformative force in biotechnology with a profound impact on medical science and patient health.

Ionis Pharmaceuticals
ionispharma.com

Twist Bioscience

Orbital Therapeutics

ReviR Therapeutics
revirtx.com

Ochre Bio
ochre-bio.com

Wayfinder Biosciences
wayfinderbio.com

Wave Therapeutics

LifeWave

Kymera Therapeutics
kymeratx.com

Alnylam Pharmaceuticals aln
alnylam.com

Astria Therapeutics
astriatx.com

Walden Biosciences

Wave
wavelife.io

Alltrna
alltrna.com

Cogent Biosciences
cogentbio.com
Companies similar to Wave Life Sciences include Ionis Pharmaceuticals, Twist Bioscience, Orbital Therapeutics and ReviR Therapeutics.
Wave Life Sciences was founded in 2012.
Wave Life Sciences' headquarters is located in Cambridge, MA, US.
Wave Life Sciences' most recent funding round was for $100M (USD) in December 2023.
As of Dec 7, 2023, Wave Life Sciences has raised a total of $324M (USD).
Wave Life Sciences has 217 employees as of Feb 5, 2024.